Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Zhalet Baharestan

Internal Medicine Louisville, KY Doctor of Osteopathy

NPI 1962489559 CMS profile 361283

3920 Dutchmans Ln, Suite 305, Louisville, KY 40207

Open in the dashboard

General payments

$7,949

483 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Zhalet Baharestan of Louisville, KY is reported in the CMS Open Payments database as having received $7,949 across 483 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,072 50
2024 General $1,046 56
2023 General $1,106 63
2022 General $999 69
2021 General $1,655 103
2020 General $1,262 83
2019 General $807 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Zhalet Baharestan
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Zhalet Baharestan were reported at $1,072. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Zhalet Baharestan Internal Medicine median Middle half National median
2019 $807 $159 $48–$570 $163
2020 $1,262 $119 $33–$402 $114
2021 $1,655 $135 $37–$521 $132
2022 $999 $141 $42–$496 $149
2023 $1,106 $149 $45–$519 $160
2024 $1,046 $154 $47–$537 $164
2025 $1,072 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,289 69 payments
  2. Amgen Inc. $881 58 payments
  3. Novo Nordisk Inc $868 43 payments
  4. AbbVie, Inc. $737 51 payments
  5. Merck Sharp & Dohme Corporation $351 24 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $326 25 payments
  7. Pfizer Inc. $325 14 payments
  8. GlaxoSmithKline, LLC. $311 20 payments
  9. Lilly USA, LLC $267 19 payments
  10. Tris Pharma Inc $248 15 payments
  11. Other $2,347 145 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,893 479 payments
  2. Education $56 4 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $770 42 payments
  2. Repatha $545 36 payments
  3. RYBELSUS $506 26 payments
  4. Ozempic $452 29 payments
  5. BREZTRI $415 15 payments
  6. STEGLATRO $332 23 payments
  7. Otezla $313 20 payments
  8. TRELEGY ELLIPTA $311 20 payments
  9. JANUVIA $304 21 payments
  10. UBRELVY $297 22 payments
  11. Other $6,582 415 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 72 drugs

Part D claims

2,829

Median for Internal Medicine: 777

Drug cost

$394,597

Median for Internal Medicine: $73,373

Branded share of claims

24%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rybelsus Semaglutide Brand 29 $59,280
Ozempic Semaglutide Brand 30 $47,001
Bydureon Bcise Exenatide Microspheres Brand 25 $31,520
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 41 $29,962
Jardiance Empagliflozin Brand 25 $29,718
Xigduo Xr Dapaglifloz Propaned/Metformin Brand 27 $26,036
Farxiga Dapagliflozin Propanediol Brand 15 $23,099
Repatha Sureclick Evolocumab Brand 16 $19,834
Eliquis Apixaban Brand 31 $18,951
Synjardy Xr Empagliflozin/Metformin Hcl Brand 14 $18,683

The 10 drugs with the highest cost, of 72 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$126,529

Of which drugs: $66,512

Medicare patients

171

Average age 73

Services billed

4,080

104 women, 67 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Osteoporosis 34%
Arthritis 32%
Diabetes 27%
Ischemic heart disease 25%
Atrial fibrillation 15%
Chronic kidney disease 15%
Cancer 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 31 2,881 $59,320
Pcv20 vaccine im 90677 Office 17 17 $4,655
Influenza virus vaccine, quadrivalent (aiiv4), inactivated, adjuvanted, preservative free, for injection into muscle, 0.5 ml dosage 90694 Office 19 20 $1,440
Vaccine for influenza for injection into muscle 90653 Office 13 13 $1,064
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 13 16 $11

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $163
$163 — —
Dyanavel XR
  • Tris Pharma Inc $137
$137 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $95
$95 15 —
Xelstrym
  • Noven Therapeutics, LLC $74
$74 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $59
  • Lilly USA, LLC $8
$66 25 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

483 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record